BRILLIANCE trial

BRILLIANCE trial

Credit: OHSU/Kristyna Wentz-Graff

Andreas Lauer, M.D., right, performs the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial at Oregon Health & Science University's Casey Eye Institute. The study uses the gene-editing technology CRISPR to repair mutations in the CEP290 gene that cause a rare form of inherited blindness called Leber congenital amaurosis type 10. The trial is sponsored by Allergan plc. and Editas Medicine. (OHSU/Kristyna Wentz-Graff)

Download Photo (18.5 MB)